Suggestions
Gilmore ONeill
Chief Medical Officer at Sarepta Therapeutics
Gilmore O'Neill is a prominent figure in the biopharmaceutical industry, currently serving as the Chief Executive Officer of Editas Medicine, a position he has held since June 2022. Prior to this role, he was the Executive Vice President of Research and Development and Chief Medical Officer at Sarepta Therapeutics from June 2018 until December 2021. His leadership at Sarepta was marked by overseeing the development of innovative therapies for rare neuromuscular diseases, particularly focusing on Duchenne muscular dystrophy (DMD) .135
Educational Background
Dr. O'Neill holds a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard Medical School, specializing in neurology. He also completed his residency in neurology at Massachusetts General Hospital .25
Career Highlights
- Sarepta Therapeutics (2018-2021): At Sarepta, Dr. O'Neill was instrumental in leading clinical development and regulatory strategy for several RNA and gene therapeutic programs. His efforts contributed to the advancement of multiple pipeline candidates aimed at treating DMD and other conditions .135
- Biogen (2003-2018): Before joining Sarepta, he spent over 15 years at Biogen, where he held various senior roles, including Senior Vice President of Late-Stage Clinical Development. He played a key role in the development and approval of significant drugs such as Spinraza® for spinal muscular atrophy and Tecfidera® for multiple sclerosis .234
Professional Affiliations
Dr. O'Neill is also involved with several organizations beyond his corporate roles:
- He serves on the board of directors for UNITY Biotechnology, which focuses on therapeutics for age-related diseases.
- He is a member of the American Academy of Neurology, reflecting his commitment to advancing neurological health .25
Vision and Impact
Throughout his career, Dr. O'Neill has been recognized for his deep expertise in neurobiology and genetic medicine, successfully guiding numerous clinical programs from inception through regulatory approval. His vision is centered on leveraging genetic medicine to improve patient outcomes, particularly for those with rare diseases .135
Highlights


